Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Urogen Pharma Ltd (URGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 502,187
  • Shares Outstanding, K 13,751
  • Annual Sales, $ 1,130 K
  • Annual Income, $ -75,660 K
  • 60-Month Beta 1.33
  • Price/Sales 457.88
  • Price/Cash Flow N/A
  • Price/Book 2.16

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -1.22
  • Number of Estimates 5
  • High Estimate -1.11
  • Low Estimate -1.33
  • Prior Year -1.14
  • Growth Rate Est. (year over year) -7.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
35.52 +2.82%
on 05/23/19
39.97 -8.63%
on 05/09/19
-0.54 (-1.46%)
since 04/24/19
3-Month
34.61 +5.52%
on 03/08/19
42.32 -13.71%
on 02/25/19
-4.82 (-11.66%)
since 02/22/19
52-Week
34.61 +5.52%
on 03/08/19
61.93 -41.03%
on 05/31/18
-23.96 (-39.62%)
since 05/24/18

Most Recent Stories

More News
UroGen Pharma Reports First Quarter 2019 Financial Results and Recent Corporate Developments

--Completion of UGN-101 Rolling NDA Submission to the FDA On Track for 2H 2019

URGN : 36.52 (-2.77%)
UroGen Delivers Updated Complete Response (CR) and Durability Data from the UGN-101 Phase 3 OLYMPUS Trial

--Six-month Durability Strong with 89 Percent of Evaluable Patients Remaining in CR

URGN : 36.52 (-2.77%)
UroGen Pharma to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019

UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report first quarter 2019 financial results on Thursday, May 9, 2019, prior to the open of the market. The announcement will...

URGN : 36.52 (-2.77%)
UroGen Pharma Announces Early Stage Feasibility Agreement with Janssen

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of uro-oncology, today announced that it has entered...

URGN : 36.52 (-2.77%)
New Research: Key Drivers of Growth for Ironwood Pharmaceuticals, State Street, CMS Energy, Virtus Investment Partners, Capstone Turbine, and UROGEN PHARMA -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD),...

CPST : 0.85 (+3.66%)
STT : 58.97 (+0.56%)
VRTS : 111.59 (+2.33%)
URGN : 36.52 (-2.77%)
IRWD : 11.08 (unch)
CMS : 57.24 (-0.19%)
UroGen Pharma Announces Presentation of Analysis from Phase 3 OLYMPUS Trial of UGN-101 for Patients with Low-Grade Upper Tract Urothelial Cancer

UroGen Pharma Ltd.(Nasdaq: URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced a new presentation from the pivotal...

URGN : 36.52 (-2.77%)
UroGen Pharma to Present at March 2019 Investor Conferences

UroGen Pharma Ltd. (Nasdaq:URGN), today announced that management will present at two investor conferences in March:

URGN : 36.52 (-2.77%)
UroGen Pharma to Report Fourth Quarter and Full Year 2018 Financial Results

--Acceleration of Pre-Commercial Activities and Infrastructure Buildout Underway to Support the Potential U.S. Approval and Launch of UGN-101 in 1H 2020

URGN : 36.52 (-2.77%)
UroGen Pharma to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, February 28, 2019

UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report fourth quarter and full year 2018 financial results on Thursday, February 28, 2019, prior to the open of the market. The...

URGN : 36.52 (-2.77%)
Factors of Influence in 2019, Key Indicators and Opportunity within Toyota Motor, UROGEN PHARMA, Macerich, Cosan, Middlesex Water, and Howard Hughes -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Toyota Motor Corporation...

CZZ : 11.66 (-0.17%)
HHC : 107.60 (+0.86%)
URGN : 36.52 (-2.77%)
TM : 118.55 (+0.92%)
MSEX : 61.00 (+0.74%)
MAC : 40.41 (+0.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade URGN with:

Business Summary

UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen...

See More

Key Turning Points

2nd Resistance Point 39.03
1st Resistance Point 37.78
Last Price 36.52
1st Support Level 35.82
2nd Support Level 35.11

See More

52-Week High 61.93
Fibonacci 61.8% 51.49
Fibonacci 50% 48.27
Fibonacci 38.2% 45.05
Last Price 36.52
52-Week Low 34.61

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar